Dyslipidemia – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s dyslipidemia forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of dyslipidemai?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of dyslipidemai?
- Of all people diagnosed with dyslipidemia, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dyslipidemia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Note: Coverage may vary by country.
Vivek Pathania, M.P.H., Epidemiologist, Epidemiology. Previously, he worked as a data manager in HIV Sentinel Surveillance (HSS). He completed his master’s in public health with a specialization in epidemiology from the Postgraduate Institute of Medical Education and Research in Chandigarh, India. He also holds a postgraduate degree in biotechnology.
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.